Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMND Clearmind Medicine, Inc.

Trading 03-10 13:04:10 EDT

1.05

+0.03

+2.45%

High1.18	Low1.02	Vol247.97K
Open1.02	D1 Closing1.02	Amplitude15.62%
Mkt Cap1.88M	Tradable Cap1.46M	Total Shares1.79M
T/O273.38K	T/O Rate17.72%	Tradable Shares1.40M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":1.045,"timestamp":1773162207427,"preClose":1.02,"halted":0,"volume":247972,"delay":0,"changeRate":0.02450980392156854,"floatShares":1399400,"shares":1794800,"eps":-30.35,"marketStatus":"Trading","change":0.025,"latestTime":"03-10 13:04:10 EDT","open":1.02,"high":1.1793,"low":1.02,"amount":273380.94692400005,"amplitude":0.156176,"askPrice":1.06,"askSize":480,"bidPrice":1.04,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-30.35,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773172800000},"marketStatusCode":2,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":1.02,"preHourTrading":{"tag":"盘前","latestPrice":1.03,"preClose":1.02,"latestTime":"09:26 EDT","volume":6387,"amount":6931.3237719,"timestamp":1773149182188,"change":0.01,"changeRate":0.009804,"amplitude":0.127843},"postHourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.02,"latestTime":"19:59 EDT","volume":7303,"amount":7845.9698,"timestamp":1773100755569,"change":0.01,"changeRate":0.009804,"amplitude":0.098039},"volumeRatio":5.341701},"requestUrl":"/m/hq/s/CMND/tweets","defaultTab":"tweets","newsList":[{"id":"2616530733","title":"BRIEF-Clearmind Medicine Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUD","url":"https://stock-news.laohu8.com/highlight/detail?id=2616530733","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616530733?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:52","pubTimestamp":1772628757,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUDMarch 4 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE INC - DSMB APPROVES CONTINUATION OF P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS1XJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2616453054","title":"Clearmind Medicine Inc - Dsmb Approves Continuation of Phase I/Iia Cmnd-100 Trial in AUD","url":"https://stock-news.laohu8.com/highlight/detail?id=2616453054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616453054?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:39","pubTimestamp":1772627945,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS1XJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2616530811","title":"Clearmind Medicine wins DSMB approval to advance CMND-100 AUD trial to third cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2616530811","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616530811?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:31","pubTimestamp":1772627493,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. reported that an independent Data and Safety Monitoring Board completed a second interim review of its ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, a non-hallucinogenic neuroplastogen being studied for alcohol use disorder. The company said additional topline safety data from the second cohort of six participants showed no serious adverse events and supported continuation of the study, allowing progression to a third cohort with an 80 mg dose. The safety results have already been presented as topline findings, while further study results are expected in the future as the trial continues.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL3fbrJ8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","BK4007","BK4588","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","CMND","LU0314104364.USD","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014039.USD","BK4112","SG9999014021.USD","SG9999014005.SGD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2612628286","title":"Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2612628286","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612628286?lang=en_us&edition=fundamental","pubTime":"2026-02-20 02:05","pubTimestamp":1771524345,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. reported progress related to its proprietary non-hallucinogenic neuroplastogen MEAI , including continued advancement of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. The company said multiple cohorts have been completed and that trial data readouts will be presented in the future. Clearmind also cited preclinical obesity findings for MEAI published in ACS Pharmacology & Translational Science and noted new patent applications and a collaboration with Polyrizon to develop an intranasal formulation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL8bRMS7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLRZ","CMND"],"gpt_icon":0},{"id":"2612495827","title":"Clearmind Medicine files to sell 8.17M common shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2612495827","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612495827?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:50","pubTimestamp":1771365022,"startTime":"0","endTime":"0","summary":"16:49 EST Clearmind Medicine (CMND) files to sell 8.17M common shares for holders Published first on TheFly – the ultimate source for real-time, ma...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-files-to-sell-8-17m-common-shares-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-files-to-sell-8-17m-common-shares-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2611738899","title":"Psychedelic: Clearmind reports additional CMND-100 safety results","url":"https://stock-news.laohu8.com/highlight/detail?id=2611738899","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611738899?lang=en_us&edition=fundamental","pubTime":"2026-02-12 23:40","pubTimestamp":1770910835,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on safety results, a CEO appointment...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psychedelic-clearmind-reports-additional-cmnd-100-safety-results-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psychedelic-clearmind-reports-additional-cmnd-100-safety-results-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2610651595","title":"BRIEF-Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile Of Cmnd-100 In Ongoing Phase I/Iia Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2610651595","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610651595?lang=en_us&edition=fundamental","pubTime":"2026-02-09 23:01","pubTimestamp":1770649315,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile Of Cmnd-100 In Ongoing Phase I/Iia Clinical TrialFeb 9 (Reuters) - Clearmind Medicine Inc CM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUABXL8NY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2610657653","title":"Clearmind Medicine Reports Positive Safety Results for CMND-100 in Alcohol Use Disorder Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2610657653","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610657653?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:17","pubTimestamp":1770643033,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has announced additional positive topline safety results from the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, a proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder . The results, which have already been presented, indicate no serious adverse events and strong tolerability, consistent with findings from the first cohort. The multinational, multicenter study is assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. The second cohort completed treatment at sites including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL8cyFWw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4007","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","CMND","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","SG9999014021.USD","SG9999014039.USD","BK4585","SG9999014005.SGD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2610653634","title":"Clearmind Medicine Inc - Safety Data Show No Serious Adverse Events in Second Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2610653634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610653634?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:17","pubTimestamp":1770643020,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUABXL8NY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2610636653","title":"Clearmind Medicine Inc - Announces Positive Safety Results From Phase I/Iia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2610636653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610636653?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:17","pubTimestamp":1770643020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUABXL8NY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2610765653","title":"Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2610765653","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610765653?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:17","pubTimestamp":1770643020,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, Feb.  09, 2026  (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the \"Company\"), a clinical-stage biotech company focused on the discovery an","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/09/3234516/0/en/Clearmind-Medicine-Announces-Additional-Topline-Positive-Safety-Results-Reinforcing-Favorable-Profile-of-CMND-100-in-Ongoing-Phase-I-IIa-Clinical-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2609962715","title":"BRIEF-Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAI","url":"https://stock-news.laohu8.com/highlight/detail?id=2609962715","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609962715?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:30","pubTimestamp":1770384643,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAIFeb 6 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nFWN3Z20V9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007","PLRZ"],"gpt_icon":0},{"id":"2609596155","title":"BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2609596155","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609596155?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:25","pubTimestamp":1770384335,"startTime":"0","endTime":"0","summary":"BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery** Shares of drug developer Polyrizon PLRZ.O rise 12.6% to $14.00 premarket ** Co says it will develop an intranasal version of Clearmind’s CMND.O experimental MEAI therapy, being studied for addiction-related brain disorders** CNMD's shares were up 20% at $1.7 premarket** CNMD's MEAI is designed to reshape neural pathways without hallucinations; intranasal delivery may help faster absorption and bypass the liver, per co** Co says its gel-like nasal platform aims to keep drugs longer in the nose and improve targeted delivery** PLRZ shares down over 99%, CNMD down ~41% in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL4N3Z21E3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","CMND","BK4007"],"gpt_icon":0},{"id":"2609953545","title":"Clearmind Medicine Enters Into Development Agreement to Advance Intranasal Formulation for Its Proprietary Non-Hallucinogenic Neuroplastogen Meai","url":"https://stock-news.laohu8.com/highlight/detail?id=2609953545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609953545?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:55","pubTimestamp":1770382530,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nFWN3Z20V9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND","PLRZ"],"gpt_icon":0},{"id":"2609259539","title":"Polyrizon Partners with Clearmind to Develop Intranasal MEAI Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2609259539","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609259539?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:55","pubTimestamp":1770382510,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd., a pre-clinical-stage biotechnology company, has entered into a development agreement with Clearmind Medicine Inc., a clinical-stage biopharmaceutical firm. The collaboration focuses on developing a proprietary intranasal formulation of MEAI, Clearmind's next-generation, non-hallucinogenic neuroplastogen drug candidate aimed at treating addiction-related and other central nervous system conditions. Polyrizon will leverage its advanced intranasal delivery platform to enhance the clinical development of MEAI, offering targeted delivery and potentially faster absorption. The partnership is expected to support Clearmind's future clinical programs and highlights Polyrizon's expertise in specialized intranasal drug delivery solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL95mddZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","SG9999014039.USD","SG9999014005.SGD","CMND","NDAQ","SG9999014021.USD","BK4007","IE00BGHQF748.EUR","BK4585","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","BK4588","LU0314104364.USD"],"gpt_icon":0},{"id":"2609595351","title":"Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2609595351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609595351?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:55","pubTimestamp":1770382500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nTUA32DWG8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PLRZ","CMND"],"gpt_icon":0},{"id":"2609431390","title":"Clearmind Medicine Issues $2.5 Million in Convertible Promissory Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2609431390","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609431390?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:17","pubTimestamp":1770239825,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has announced the issuance and sale of convertible promissory notes to investors, as part of previously disclosed securities purchase agreements. The company will issue promissory notes in an aggregate principal amount of $2,500,000, with investors paying a total purchase price of $2,250,000 in cash . The offering will occur in two tranches: the first tranche, totaling $600,000 in principal for $540,000 in cash, closed on February 4, 2026. The second tranche, with a principal amount of $1,900,000 for $1,710,000 in cash, will close after Clearmind files a registration statement with the SEC covering the resale of shares issuable upon conversion of the notes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL4vD6pZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2609196313","title":"Clearmind Medicine gibt Ausgabe von Wandelanleihen im Gesamtwert von 2,5 Millionen US-Dollar bekannt","url":"https://stock-news.laohu8.com/highlight/detail?id=2609196313","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609196313?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:17","pubTimestamp":1770239825,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL6KBF6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2608871679","title":"Clearmind Medicine welcomes inclusion of MEAI in bipartisan legislation","url":"https://stock-news.laohu8.com/highlight/detail?id=2608871679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608871679?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:15","pubTimestamp":1770124525,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) welcomes the inclusion of its proprietary compound, MEAI, in newly introduced bipartisan legislation in the U.S. Congress...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-welcomes-inclusion-of-meai-in-bipartisan-legislation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-welcomes-inclusion-of-meai-in-bipartisan-legislation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2608879372","title":"Clearmind Medicine erzielt Durchbruch mit MEAI in US-Gesetz für innovative Veteranen-Therapien","url":"https://stock-news.laohu8.com/highlight/detail?id=2608879372","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608879372?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:01","pubTimestamp":1770123662,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL82sS3F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014039.USD","IE00B3QW5Z07.USD","BK4585","IE00B64PRP62.GBP","LU2095319765.USD","LU2210150020.SGD","CMND","IE00BKPKM429.USD","BK4588","BK4112","BK4007","LU2210149790.SGD","NDAQ","SG9999014005.SGD","SG9999014021.USD","SG9999014013.SGD","IE00BGHQF748.EUR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":-0.1639},{"period":"1month","weight":-0.2444},{"period":"3month","weight":-0.7905},{"period":"6month","weight":-0.9751},{"period":"1year","weight":-0.9759},{"period":"ytd","weight":-0.4365}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.04},{"period":"1year","weight":0.1777},{"period":"ytd","weight":-0.0054}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.040615},{"month":2,"riseRate":0.25,"avgChangeRate":-0.154491},{"month":3,"riseRate":0,"avgChangeRate":-0.285071},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.169588},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.01702},{"month":6,"riseRate":0.333333,"avgChangeRate":0.080414},{"month":7,"riseRate":0.333333,"avgChangeRate":0.008507},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.088917},{"month":9,"riseRate":0,"avgChangeRate":-0.22938},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.107561},{"month":11,"riseRate":0,"avgChangeRate":-0.304445},{"month":12,"riseRate":0.25,"avgChangeRate":-0.256594}],"exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction